Giants of Cancer Care® Program Inductees

Translational Science

Charles Swanton, MD, PhD

The Francis Crick Institute
Universy College London Cancer Institute

Swanton is chief clinician and director of Cancer Research UK Lung Cancer Centre of Excellence, chair in personalized cancer medicine at the University College London Hospitals, and principal group leader at The Francis Crick Institute.
Research efforts from his laboratory discovered that cancer cytotoxics, human leukocyte antigens, loss of heterozygosity, cancer genome doubling events, DNA replication stress, and the APOBEC3B cytidine deaminase precipitate cancer diversity. In turn, this accelerates cancer evolution and is the foundation for treatment resistance and failure.
His laboratory, the Cancer Evolution and Genome Instability Laboratory, has conducted several seminal first-in-human studies elucidating requirements for effective immune-based therapies, which uses a uniform population of ex vivo expanded antigen-specific T cells.
Swanton is the principal investigator of the TRACERx clinical trial (NCT01888601), which is investigating the genomic landscape of non–small cell lung cancer and is designed to determine how tumors evolve, metastasize, and develop resistance. The study aims to collect and analyze genomic data to identify patients who could benefit from trials of new targeted treatments in the United Kingdom.

Home

)

SUPPORTED BY